Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a digital tool help High-Risk patients decide on pancreatic cancer screening?

NCT ID NCT07808671

Diagnosis Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Pancreatic cancer is hard to catch early, and screening guidelines for high-risk people remain uncertain. Researchers at UNC are testing an electronic decision support tool that guides patients and doctors through a shared conversation about whether to screen. The pilot study enrolls 40 adults eligible for pancreatic cancer screening and measures whether the tool is acceptable, feasible, and usable in clinic. It also checks whether patients learn more about the screening decision.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an electronic decision support tool for shared decision-making about pancreatic cancer screening
What this could lead to
If it works, the tool could give high-risk patients and their doctors a clearer, more structured way to weigh the uncertain benefits and harms of pancreatic cancer screening.
What could go wrong
This is a small pilot study of 40 people at one clinic, so it cannot show whether the tool improves outcomes or saves lives. It only tests whether people find it usable and whether it fits into real clinic visits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults who are eligible for pancreatic cancer screening according to current National Comprehensive Cancer Network guidelines. * Not currently enrolled in a pancreatic cancer screening program. * Referred to or previously seen at the UNC High Risk GI Cancer Clinic. * English-speaking. * Able and willing to provide informed consent. Exclusion Criteria: * Currently enrolled in a pancreatic cancer screening program. * Does not meet pancreatic cancer screening eligibility criteria according to National Comprehensive Cancer Network guidelines. * Unable or unwilling to provide informed consent. * Non-English speaking.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreas cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreas cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of North Carolina at Chapel Hill, Department of Gastroenterology and Hepatology

    Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.